Fortis Gurugram Hosts ‘HemeNext 1.0’: Showcases Breakthroughs in Genomics, AI, Cell Therapy & Healthcare Robotics for the Future of Hematology

Chandigarh, November 26, 2025: As India faces a growing burden of blood cancers, immune disorders, and complex infections, early diagnosis and personalized treatment have become more critical than ever. In response, Fortis Memorial Research Institute (FMRI), Gurugram organised HemeNext 1.0 - a pioneering national scientific conference showcasing how Genomics, Artificial Intelligence (AI), robotics, and next-generation Cell Therapies are reshaping the future of hematology and infectious diseases.
The two-day conference brought together over 150 leading clinicians in person and more than 1,700 participants online, including hematologists, infectious disease specialists, BMT physicians, CAR-T innovators, and young clinicians from across India.
A standout attraction at HemeNext 1.0 was India’s First Humanoid Healthcare Host ‘Hembot’, a life-sized humanoid robot powered by NVIDIA Jetson Orin, capable of 100 trillion AI operations per second.
Hembot greeted delegates, guided them to sessions, co-hosted on-stage discussions and interacted with guests throughout the conference, showcasing how future hospitals may use humanoid robots for:
•             Patient navigation and education
•             Clinical information support
•             Monitoring assistance
•             Hospitality and engagement in OPDs and waiting areas
The robot also joined the gala evening, welcomed participants, and performed synchronized movements, symbolizing FMRI’s vision for AI-integrated, next-generation healthcare.
Central to HemeNext 1.0 was Genomics, which is now redefining how hematologists diagnose and treat conditions such as leukemia, lymphoma, bone marrow failure syndromes, and inherited blood disorders.
 
Key insights included:
•             Next-Generation Sequencing (NGS) for deep cancer profiling
•             Gene mutation & expression analysis for sharper diagnostic accuracy
•             Relapse prediction using genomic algorithms
•             Clonal evolution tracking to understand disease progression
•             Genomics-based donor matching for safer, more successful bone marrow transplants
 
These tools are helping clinicians shift from generic treatments to highly personalised, data-driven care, leading to better outcomes and fewer complications.The conference placed significant emphasis on strengthening day-to-day clinical decision-making through real-world case discussions and mentorship-led learning.
 
HemeNext 1.0 showcased how scientific progress is directly improving patient care:
•             Faster diagnosis of blood cancers with AI-powered tools
•             More accurate genetic reports with advanced genomics
•             New therapies like CAR-T offering hope for difficult-to-treat cancers
•             Robotics assisting doctors for precision and patient support
•             Safer bone marrow transplants through genomics-based donor matching
•             Better survival rates with personalized, data-driven treatment plans
 
Dr. Rahul Bhargava, Principal Director & Chief – Hematology, Hemato Oncology & Bone Marrow Transplant, FMRI, said: “At Fortis, we have built one of India’s most comprehensive hematology ecosystems, bringing together genomics, advanced diagnostics, cell therapies, and AI-driven tools under one roof. HemeNext 1.0 reflects our commitment to pushing scientific boundaries and redefining hematology care for the country.”
Dr. Vikas Dua, Principal Director & Head – Pediatric Hematology, Hemato Oncology & BMT, FMRI, added “Pediatric hematology demands precision and innovation. HemeNext 1.0 strengthens our mission to give children battling blood cancers and rare disorders access to the most advanced, evidence-based care.”
Yash Rawat, Senior Vice President & SBU Head,FMRI said: “FMRI is emerging as India’s precision-hematology hub. With genomics-led workflows, AI-assisted diagnostics, next-generation therapies like CAR-T, and now humanoid robotics, Fortis Gurugram is shaping the future of integrated, high-end hematology care.”